Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy
into Clinical Trials
Stockholm, Sweden - Dec 15, 2009 - Biovitrum AB (publ) (STO: BVT)
today announced that the first patient was dosed in a phase I/IIa
study of its long-acting fully-recombinant Factor VIII Fc fusion
(rFVIIIFc) protein. The phase I/IIa open-label study will assess the
safety, tolerability and pharmacokinetics of rFVIIIFc in severe,
previously-treated, hemophilia A patients. The rFVIIIFc program and
international study are partnered with Biogen Idec (NASDAQ: BIIB).
Hemophilia A patients require frequent Factor VIII injections, which
create a significant burden for these individuals. The rFVIIIFc
molecule is being investigated for the potential to prolong
protection from bleeding and reduce the frequency of injections for
both prophylaxis and on-demand therapy in Hemophilia A. Preclinical
studies showed improved half-life of rFVIIIFc, which is based on
Biogen Idec's monomeric Fc-fusion technology (recently presented 7
December 2009 at the American Society of Hematology conference).
"We are excited about bringing rFVIIIFc into the clinical stage
together with Biogen Idec and, thereby adding another significant
collaboration project to the ongoing recombinant Factor IX Fc fusion
(rFIXFc) clinical program. The innovative rFVIIIFc program holds
great potential in offering true value to hemophilia A patients, and
is thus a prioritized therapeutic and business area within
Biovitrum," said Peter Edman, CSO of Biovitrum.
About Hemophilia A
Hemophilia A is a rare, inherited disorder in which the ability of a
person's blood to clot is impaired. Hemophilia A occurs in about 1 in
10,000 male births annually and is caused by having substantially
reduced or no factor VIII protein, which is needed for normal blood
clotting. People with hemophilia A therefore need injections of
factor VIII to restore the coagulation process and prevent frequent
bleeds that could otherwise lead to pain, irreversible joint damage
and life-threatening hemorrhages. Prophylaxis treatment with
infusions three times per week or every second day to maintain a
sufficient circulating level of coagulation factor is being
increasingly used, and long-term studies demonstrate that such
regimens increase the patient's life expectancy and greatly reduce if
not eliminate progressive joint deterioration. The current global
market for recombinant Factor VIII products is over 4 BUSD annually.
About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. The company has revenues of approximately SEK 1.2
billion and around 400 employees. The company head office is located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For
more information please visit www.biovitrum.com.
For more information please contact:
Biovitrum AB (publ)
Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com
Peter Edman, CSO
Phone: +46 8 697 21 77
Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on December 15, 2009 at
08:30 a.m. CET.